AnaptysBio, Inc.

Today, ANAB trades at 47.73 USD.

For broader market analysis, dive into the technicals on the AnaptysBio, Inc. stock price chart and read the latest ANAB news:
– AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
– AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug
– AnaptysBio, Inc. (ANAB) Jemperli Wins FDA Nod for MSI-H/dMMR Rectal Cancer

Markets don't sleep, here's what's going on with ANAB at the moment:
– AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
– AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug
– AnaptysBio, Inc. (ANAB) Jemperli Wins FDA Nod for MSI-H/dMMR Rectal Cancer

See more updates in real-time with our News Flow.

ANAB stock is 3.04% volatile and has beta coefficient of 0.65.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ANAB are typically less volatile than smaller companies

Track every detail on AnaptysBio, Inc. stock chart and check out the list of the most volatile stocks — is AnaptysBio, Inc. there?

To understand the ANAB stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +1.75%
– 1 week — −3.07%
– 1 month — −2.53%

ANAB all-time low was 6.67 USD (Nov 8, 2019), and its highest price is 89.32 USD (Feb 20, 2018). Find more dynamics in the Stock Heatmap and on the AnaptysBio, Inc. stock chart.

AnaptysBio, Inc. market capitalization is ‪1.40 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from AnaptysBio, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how AnaptysBio, Inc. stacks up against other companies

The safest way to buy AnaptysBio, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade ANAB directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

As of Nov 4, 2026, the company has 104 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

Investing in AnaptysBio, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.

First, study AnaptysBio, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency

Then explore our ANAB technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — neutral
– 1-month — buy

Combine fundamental and technical analysis for better results.

ANAB earnings for the last quarter are 5.11 USD per share, whereas the estimation was 5.11 USD, resulting in a 0.00% surprise. The estimated earnings for the next quarter are 0.85 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in AnaptysBio, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

AnaptysBio, Inc. revenue for the last quarter amounts to ‪27.49 M‬ USD despite the estimated figure of ‪27.49 M‬ USD. In the next quarter revenue is expected to reach ‪40.10 M‬ USD.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in AnaptysBio, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

Yes, you can track AnaptysBio, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

ANAB net income for the last quarter is ‪183.88 M‬ USD, while the quarter before that showed ‪−52.88 M‬ USD of net income which accounts for 447.70% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in AnaptysBio, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

No, AnaptysBio, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends

ANAB reached its all-time high of 89.32 USD on Feb 20, 2018. Its all-time low was 6.67 USD and was reached on Nov 8, 2019.

Explore the AnaptysBio, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.

AnaptysBio, Inc. EBITDA is ‪136.11 M‬ USD, with an EBITDA margin of 21.45%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in AnaptysBio, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality